(Solid Tumors) Is Enhertu Effective?
(Solid Tumors) Is Enhertu Effective?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
(Solid Tumors) Is Enhertu Effective?
- June 28, 2023
- Read time: 1 minute
From June 2-6, 2023, Funda Meric-Bernstam and colleagues from Memorial Sloan Kettering Cancer Center presented efficacy and safety results of Enhertu treatment in HER2-positive, advanced solid tumor patients from the DPT02 Phase 2 clinical trial at ASCO 2023 in Chicago, USA.
The DPT02 Phase 2 clinical trial was an open-label trial conducted jointly at multiple facilities in the United States and Japan. HER2-positive, advanced solid tumor patients received Enhertu 5.4-6.4 mg/kg (every three weeks) until disease progression or adverse events occurred. The primary endpoint was objective response rate, with secondary endpoints including duration of response, disease control rate, progression-free survival, overall survival, and safety.
Results from 267 patients at a median follow-up of 9.7 months showed: primary endpoint objective response rate of 37.1%, secondary endpoint median duration of response of 11.8 months; in HER2-positive patients, objective response rate was 61.3% with median duration of response of 22.1 months.
Regarding safety, Grade 3+ adverse events occurred in 58.4% of patients, treatment discontinuation due to adverse events in 11.6%, and interstitial lung disease/pneumonitis in 6.7%.
Based on Phase 2 clinical trial results, Funda Meric-Bernstam and colleagues concluded: HER2-positive, advanced solid tumor patients treated with Enhertu demonstrated good response rates with controllable adverse effects. Enhertu has the potential to become a new treatment option for HER2-positive solid tumor patients.
Source: https://meetings.asco.org/abstracts-presentations/220035
Key to High-Aggressiveness Pancreatic Cancer Discovered! New Immune Enhancer Assists Cancer Immunotherapy Kyoto University Launches iPS Cell Cancer Treatment!
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4